Results 41 to 50 of about 52,376 (272)

Identification of potential prognostic biomarkers of thymoma with myasthenia gravis based on serum proteomics

open access: yesFrontiers in Immunology
BackgroundThymoma is often associated with myasthenia gravis (MG), and the resection of thymoma improves myasthenic symptoms in patients with thymoma and MG (TMG), but some patients still have no relief.
Xiaoting Lin   +11 more
doaj   +1 more source

The Muscle Is Not a Passive Target in Myasthenia Gravis

open access: yesFrontiers in Neurology, 2019
Myasthenia gravis (MG) is a rare autoimmune disease mediated by pathogenic antibodies (Ab) directed against components of the neuromuscular junction (NMJ), mainly the acetylcholine receptor (AChR).
Jean-Thomas Vilquin   +3 more
doaj   +1 more source

Myasthenia Gravis [PDF]

open access: yesThe Journal of Nervous and Mental Disease, 1902
n ...
openaire   +1 more source

Bottom‐Up Engineering of a Human Neuromuscular System for Modeling Activity‐Induced Remodeling, Metabolic Stress, and Endothelial‐Modulated Excitability

open access: yesAdvanced Materials, EarlyView.
Using a bottom‐up approach, we engineered a human neuromuscular microchip to investigate distinct adaptive responses to neural stimulation and metabolic stress. Further integration of endothelial cells revealed their critical role in modulating neuromuscular excitability, establishing a comprehensive neurovascular‐muscular model.
Jinchul Ahn   +17 more
wiley   +1 more source

Methylprednisolone pulse versus docetaxel in recurrent thymoma with myasthenia gravis

open access: yesFrontiers in Neurology
IntroductionThis study aims to compare the effectiveness and safety of methylprednisolone pulse versus docetaxel in treating recurrent thymoma with myasthenia gravis (MG).MethodsWe conducted a single-center, open-label, retrospective study that included ...
Hongxia Yang   +9 more
doaj   +1 more source

Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study [PDF]

open access: yes, 2014
Background and purpose: Comorbidity in myasthenia gravis (MG) is important for diagnosis, treatment and prognosis. Disease complexity was assessed by examining total drug treatment, immune therapy and comorbidity in a complete national MG cohort. Methods:
A. Engeland   +7 more
core   +1 more source

Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity

open access: yesAdvanced Science, EarlyView.
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten   +30 more
wiley   +1 more source

A nurse-led nomogram for predicting the risk of myasthenic crisis in patients with myasthenia gravis and bulbar weakness

open access: yesBMC Neurology
Background The present study aimed to develop and validate a nurse-led clinical prediction model for assessing the risk of myasthenic crisis (MC) in myasthenia gravis (MG) patients with bulbar weakness.
Huimin Dong   +3 more
doaj   +1 more source

MYASTHENIA GRAVIS. [PDF]

open access: yesJAMA: The Journal of the American Medical Association, 1906
n ...
openaire   +2 more sources

Thymoma with Myasthenia Gravis in Adolescent [PDF]

open access: yes, 2011
Thymomas are exceedingly rare in the first 20 years of life, Thymic lesions comprise approximately 2–3% of all pediatric mediastinal tumors and include thymic cysts, hyperplasia, carcinoma, and thymomas.
Shetty, Prasad K   +7 more
core  

Home - About - Disclaimer - Privacy